SBI Neopharma establishes footprint in the UAE

SBI Neopharma establishes footprint in the UAE

SBI Neopharma has established its footprint in the UAE by opening up an office in Dubai Healthcare City.

SBI Neopharma is a joint venture between SBI Pharmaceuticals Co. Ltd. and Neopharma LLC for the research, production and global sales for medicines, medical devices, cosmetics and health foods utilizing 5-ALA (5-aminolevulinic acid). SBI Pharmaceuticals is part of the SBI Group, a Tokyo based financial services organization with varied business interests.

Dr. BR Shetty, Executive Vice Chairman and Managing Director Neopharma inaugurated the office.  He was accompanied by the senior management of the NMC Group that included, Mr. Suresh Kumar, Chief Financial Officer, Mr. Suresh Nandiraju, Chief Operating Officer and Mr. Sumit Bhanot, Marketing Director.

SBI Neopharma’s flagship product NatuALA, contains 5-ALA, a revolutionary novel compound in the treatment of Type 2 Diabetes. NatuALA is currently available in Japan, Bahrain, Jordan and UAE.